KURA

Kura Oncology, Inc.

20.69 USD
+0.22 (+1.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kura Oncology, Inc. stock is up 5.45% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
18 Apr 19:25 19 Apr, 2024 15.00 CALL 200 363
22 May 17:39 19 Jul, 2024 22.50 CALL 95 302

About Kura Oncology, Inc.

Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.

  • JP Morgan
    Thu May 16, 12:55
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 14, 10:01
    buy
    confirm
  • JP Morgan
    Mon May 6, 11:02
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 3, 15:51
    buy
    confirm
  • Wedbush
    Fri May 3, 09:41
    buy
    confirm